Australia’s COVID-19 vaccine journey: progress and future perspectives
Open Access
- 15 March 2024
- journal article
- research article
- Published by CSIRO Publishing in Microbiology Australia
- Vol. 45 (1) , 27-31
Abstract
COVID-19 vaccines have played a pivotal role in reducing SARS-CoV-2 disease severity and mortality. However, evolutionary pressure has resulted in viral variants with increased fitness, greater capacity for immune evasion and higher infectivity. This evolution is exemplified by the emergence of the Omicron subvariants, all of which demonstrate significant escape from vaccine- or infection-induced immunity. Broadly protective vaccines are urgently needed to fight current, emerging and future SARS-CoV-2 variants. Australia is actively contributing to these efforts through the development of innovative vaccination approaches and vaccine delivery platforms.Keywords
This publication has 18 references indexed in Scilit:
- Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterEBioMedicine, 2023
- Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023Eurosurveillance, 2023
- Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based studyThe Lancet Regional Health - Western Pacific, 2023
- Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelEBioMedicine, 2023
- Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysisNature Communications, 2023
- Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concernFrontiers in Immunology, 2023
- Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trialClinical Microbiology and Infection, 2022
- The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variantsImmunity, 2022
- The vaccinia‐based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responsesImmunology & Cell Biology, 2022
- Covid 19 Vaccines and the Australian health care stateHealth Policy and Technology, 2022